Review for 10.1186/s12876-023-02661-2 (2023)

Reviewer’s report
Title: 
Real-world systemic sequential therapy with regorafenib for recurrent
hepatocellular carcinoma: analysis of 93 cases from a single center
Version: 
0 
Date: 
18 Jun 2022
Reviewer: 
Shahram Agah
Reviewer's report:
1. There are many grammatical and spelling mistakes throughout the manuscript,
including but not limited to the following:
- Page 2: Combination therapy under mutidisciplinary treatment (MDT) team
guidance could "be" effective in impeding tumor progression ...
- Page 3: Less than 30% of the patients at the first diagnosis are suitable for
radical treatment because of the concealed onset of HCC, "and for the rest of the
patients", systematic antineoplastic monotherapy ...
- Throughout the manuscript: "RESORCE" trial
- Page 3: In this study, we attempted to "identify" the factors affecting the
prognosis of patients with HCC treated with regorafenib by retrospectively
"analyzing" the clinical data and follow-up results of a group of patients with
recurrent HCC treated with regorafenib.
2. Extensive inclusion of numerical values within the text of the Results section
has made the text cluttered and hard to follow. Please make sure you have
included all data in the corresponding tables and figures (particularly for efficacy
measurements including CR, PR, PD, SD, and response rates), and dedicate the
Results section to a general overview of the main findings and more general
comparisons.
3. Please elaborate more on the adverse events following the regorafenib
treatment and dedicate a table for it.
4. Introduce the acronyms on their first use within the text.
5. Insert descriptions for tables, particularly for abbreviations.
Publons Reviewer Recognition
. Springer Nature can send verification of this
review directly to Publons (a subsidiary of Clarivate Analytics). If you would
like to take advantage of this service, please click on the “Yes” option below.
Your name, email address, title of the reviewed manuscript, name of the journal,
and date of your review submission (the “Review Data”) will then be transmitted
to Publons after the final decision on the manuscript has been made. If you have
already registered at Publons, they will notify you of the receipt of this review
and update your profile 
as per your settings and their policy. If you are not
registered with Publons, you will receive an email from them asking you to
register in order for them to be able to recognize your review on your new
profile page. Publons may use the Review Data to generate derivative metadata
for the benefit of Publons and you as a reviewer, carefully considering the
sensitivity of such information. For example, Publons may verify your record as
a reviewer by updating your profile published on its webservice if you have
registered for such service or help editors to identify candidate reviewers. Please
find the details of processing in Publons’ privacy policy
https://publons.com/about/terms
Yes
Declaration of competing interests
Please complete a declaration of competing
interests, considering the following questions:
1
. 
Have you in the past five years received reimbursements, fees, funding, or
salary from an organisation that may in any way gain or lose financially
from the publication of this manuscript, either now or in the future?
2
. 
Do you hold any stocks or shares in an organisation that may in any way
gain or lose financially from the publication of this manuscript, either now
or in the future?
3
. 
Do you hold or are you currently applying for any patents relating to the
content of the manuscript?
4
. 
Have you received reimbursements, fees, funding, or salary from an
organization that holds or has applied for patents relating to the content of
the manuscript?
5
. 
Do you have any other financial competing interests?
6
. 
Do you have any non-financial competing interests in relation to this
paper?
If you can answer no to all of the above, write 'I declare that I have no competing
interests' below. If your reply is yes to any, please give details below.
I declare that I have no competing interests.
Reviewer Publication Consent.
 I agree for my report to be made available
under an Open Access Creative Commons CC-BY License (
http://creativecommons.org/licenses/by/4.0
) if this manuscript is accepted for
publication. Any comments that I do not wish to be included in the published
report have been included as confidential comments to the editor, which will not
be published.
If you are not happy for us to publish this report, please contact the
editorial office before completing the review.
If you wish, you can include your
name in your published report. Please note you must decide whether to include
your name at the start of the process and confirm this decision whenever
prompted. If you change your decision later, we will not be able to publish your
name.
I agree to the terms of the CC-BY 4.0 license; please publish my name with my
report.
Is the study design appropriate to answer the research question (including the use
of appropriate controls), and are the conclusions supported by the evidence
presented?
Yes
Are the methods sufficiently described to allow the study to be repeated?
Yes
Is the use of statistics and treatment of uncertainties appropriate?
Yes
Is the presentation of the work clear?
Yes
Are the images in this manuscript (including electrophoretic gels and blots) free
from apparent manipulation?
Yes